A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Trial Profile

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs INCB 54828 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms FIGHT-203
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 05 Apr 2017 Primary analysis is expected in January 2019 as per trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 02 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top